[Pilot clinical study on the use of a new nonsteroid anti-inflammatory drug (flunoxaprofen) in arthrosis pathology].
Twenty-five patients (10 males and 15 females, mean age 56.5 years) suffering from osteoarthritis were admitted to a clinical trial in order to evaluate the efficacy and long-term tolerability of Flunoxaprofen, a new non-steroidal anti-inflammatory compound. Flunoxaprofen 100 mg was given orally twice a day to the patients for a 60 days period. The variables involving the clinical effectiveness of Flunoxaprofen, especially pain and joint motion range, assessed every two weeks showed a considerable and progressive improvement of the symptoms all along the period of treatment. Blood chemistry, hematology and urinalysis, performed routinely on every patient concurrently with their pre-treatment and subsequent clinical assessments, showed the remarkable tolerability of the drug.